Zur Kurzanzeige

dc.creatorGogou E., Hatzoglou C., Zarogiannis S.G., Siachpazidou D., Gerogianni I., Kotsiou O.S., Varsamas C., Gourgoulianis K.I.en
dc.date.accessioned2023-01-31T07:43:29Z
dc.date.available2023-01-31T07:43:29Z
dc.date.issued2022
dc.identifier10.1016/j.rmed.2022.106988
dc.identifier.issn09546111
dc.identifier.urihttp://hdl.handle.net/11615/72563
dc.description.abstractInfluenza and pneumococcal pneumonia are major causes of increased morbidity and mortality among elderly and COPD patients. Vaccines against influenza and pneumococcus are recommended for COPD patients according to GOLD 2020 guidelines to prevent serious illnesses. Despite their high morbidity and mortality burden, the vaccination coverage rates remain far below the WHO's recommended targets. In Greece, there are insufficient data on influenza and pneumococcal immunization rates among younger COPD patients. This study investigated whether COPD patients under the age of 65 are adequately vaccinated against influenza and pneumococcus and the factors that influence vaccination rates. 1100 individuals at 22 Primary Health Centers in Central Greece participated in a two-year spirometry monitoring program. Face-to-face interviews were used to collect information regarding demographics, smoking status, comorbidities, respiratory illnesses in the previous two years, and influenza and pneumococcal vaccination coverage from all COPD patients. 117 patients aged 40–65 years old were diagnosed with COPD and 80.3% were males. Only 40.2% of them had received influenza and 32.5% pneumococcus vaccinations. Age, advanced stage of COPD, years on COPD diagnosis, respiratory infection within the previous two years, comorbidity, and smoking cessation are all positively connected with influenza and pneumococcus vaccine coverage in younger COPD patients. Gender, education level, and marital status did not affect influenza and pneumococcus vaccination rates. These vaccination rates among younger COPD patients demonstrate the need for increased awareness and knowledge about the advantages of immunizations in lowering morbidity and mortality. © 2022 Elsevier Ltden
dc.language.isoenen
dc.sourceRespiratory Medicineen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85138592725&doi=10.1016%2fj.rmed.2022.106988&partnerID=40&md5=921a752d86a11e0be25db3728d99d657
dc.subjectbronchodilating agenten
dc.subjectinfluenza vaccineen
dc.subjectPneumococcus vaccineen
dc.subjectPneumococcus vaccineen
dc.subjectadulten
dc.subjectageden
dc.subjectArticleen
dc.subjectchronic obstructive lung diseaseen
dc.subjectcomorbidityen
dc.subjectdemographicsen
dc.subjecteducational statusen
dc.subjectfemaleen
dc.subjectGreeceen
dc.subjecthealth centeren
dc.subjecthigh risk populationen
dc.subjecthumanen
dc.subjectinfluenzaen
dc.subjectinfluenza vaccinationen
dc.subjectinterviewen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmarriageen
dc.subjectmedical informationen
dc.subjectmiddle ageden
dc.subjectmorbidityen
dc.subjectmortality rateen
dc.subjectpeople by smoking statusen
dc.subjectrespiratory tract infectionen
dc.subjectrespirometryen
dc.subjectsmoking cessationen
dc.subjectStreptococcus pneumoniaen
dc.subjectStreptococcus pneumoniaeen
dc.subjectvaccinationen
dc.subjectvaccination coverageen
dc.subjectchronic obstructive lung diseaseen
dc.subjectinfluenzaen
dc.subjectStreptococcus pneumoniaeen
dc.subjectvaccinationen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInfluenza Vaccinesen
dc.subjectInfluenza, Humanen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPneumococcal Vaccinesen
dc.subjectPulmonary Disease, Chronic Obstructiveen
dc.subjectStreptococcus pneumoniaeen
dc.subjectVaccinationen
dc.subjectW.B. Saunders Ltden
dc.titleAre younger COPD patients adequately vaccinated for influenza and pneumococcus?en
dc.typejournalArticleen


Dateien zu dieser Ressource

DateienGrößeFormatAnzeige

Zu diesem Dokument gibt es keine Dateien.

Das Dokument erscheint in:

Zur Kurzanzeige